Ramona Doyle - Feb 28, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Feb 28, 2022
Transactions value $
$38,750
Form type
4
Date filed
3/1/2022, 07:00 PM
Previous filing
Feb 8, 2022
Next filing
Apr 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $38.8K +15.6K +16.07% $2.48 113K Feb 28, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -15.6K -2.25% $0.00 678K Feb 28, 2022 Class A Common Stock 678K $2.48 Direct F1
holding RXRX Stock Option (Right to Buy) 77K Feb 28, 2022 Class A Common Stock 77K $11.40 Direct F2
holding RXRX Stock Option (Right to Buy) 4.78K Feb 28, 2022 Class A Common Stock 4.78K $11.40 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.
F2 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.